Multidomain lifestyle intervention
Studies of multidomain lifestyle intervention in people
82 studies gave multidomain lifestyle intervention to people and measured what changed
| What changed | Design | People | Source |
|---|---|---|---|
up: Improves health-related quality of life down: Prevents depressive symptoms | Randomized trial8 weeks | 30 peopleMild cognitive impairment | Neuroscience, Oct 31, 2026 |
up: Increases seattle Angina Questionnaire summary scoreAdjusted between-group difference +7.10 points (95% CI 0.87–13.30; p=0.026) | Randomized trial12 months | 123 peopleMenANOCA | ESC Congress 2026 abstract, Oct 26, 2026 |
no change: Has no effect on body weightb = -0.30, 95% CI: -0.51; 1.11 no change: Has no effect on motivation and confidence regarding weight lossOR = 1.07, 95% CI: 0.78; 1.46 | Randomized trial24 months | 678 peopleBoth60–77 years; mean 68.9 years (SD 4.8)Older adults with overweight or obesity at risk of dementia | BMC geriatrics, Oct 15, 2026 |
no change: Has no effect on AD plasma biomarker trajectories | Randomized trialtwo years | 1,260 people46.9% were womenmean age 68.8 ± 4.7 yearsCommunity-dwelling older adults at risk of dementia | medRxiv, Oct 6, 2026 |
up: Improves gait speed0.06 m/s (95% CI, 0.01 to 0.12) | Randomized trial18 months | 433 peopleBoth65-85 yearsOlder adults; mild cognitive impairment, High DVS group | Clinical nutrition ESPEN, Sep 29, 2026 |
up: Improves montreal Cognitive Assessment0.58 points, 95% CI 0.03–1.13 no change: Has no effect on trail Making Test0.16 s (95% CI −5.07 to 5.40) no change: Has no effect on skeletal muscle mass index | Randomized trial6 months | 355 peopleBothaged 65 years or olderRisk-enriched community-dwelling older population | EClinicalMedicine, Sep 23, 2026 |
up: Improves diet scoreBeta 1.67, 95% CI 0.61;2.73, PFDR=0.01 up: Improves sleep scoreBeta −1.80, 95% CI −2.79;-0.81, PFDR=0.005 no change: Has no effect on working memory performance | Randomized trialsix months | 102 people60–75 yearsOlder adults; at risk for cognitive decline and dementia | medRxiv, Jul 29, 2026 |
up: Improves cognitive functionbetween-group difference, 4.17 points; 95% CI 1.92-6.43 | Randomized trial24 weeks | 277 peopleBoth60-85 yearsOlder adults; mild cognitive impairment | Neurology, Jul 20, 2026 |
up: Improves global cognitive functionmean between-group difference 0.11 SD per year (95% CI 0.06-0.15; p<0.0001) | Randomized trial2 years | 1,065 peopleBoth60-77 yearsOlder adults | Lancet (London, England), Jul 13, 2026 |
no change: Has no effect on white matter hyperintensity volumeβ = 0.002; SE = 0.016 | Randomized trialup to 24 months | 959 peopleBoth60 to 79 yearsOlder adults | JAMA network open, Jul 1, 2026 |
down: Lowers the risk of cognitive impairmentHR = 0.64 [0.46,0.89] no change: Has no effect on cognitive impairmentHR = 0.98 [0.85,1.16] up: Raises the risk of cognitive impairmentHR = 1.40 [1.01,1.93] | Randomized trial10-year intervention, 12-14 years post-trial follow-up | 3,655 peopleBaseline BMI 25-29 kg/m2 (overweight) | Alzheimer's & dementia : the journal of the Alzheimer's Association, Jul 1, 2026 |
no change: Has no effect on global cognitive composite | Randomized trial2 years | 983 peopleBoth60 to 79 yearsOlder adults | JAMA neurology, Apr 21, 2026 |
down: Decreases frailty index-0.014 (95% CI -0.019, -0.008) up: Improves cognitive function0.076 [0.038, -0.114] | Randomized trial24 months | 2,111 peopleBoth60-79 years of ageOlder adults at risk for cognitive decline due to established demographic, lifestyle, family history, and cardiometabolic factors | The journals of gerontology. Series A, Biological sciences and medical sciences, Apr 7, 2026 |
down: Decreases blood pressureto approximately 120/80 mmHg up: Increases physical activity | Trialeleven weeks | 12 peopleBoth50–65 yearsMidlife adults; Older adults; hypertension | APJAET - Journal ay Asia Pacific Journal of Advanced Education and Technology, Mar 16, 2026 |
down: Decreases total cholesterol-24.23 mg/dL (95% CI -28.25 to -20.22) down: Decreases LDL cholesterol-14.41 mg/dL (95% CI -18.36 to -10.45) up: Increases HDL cholesterol+7.04 mg/dL (95% CI 5.76-8.31) | Randomized trial24 months | 1,671 peopleBothmean age 40.8 yearsMidlife adults; General population | Journal of clinical lipidology, Mar 13, 2026 |
down: Decreases trait impulsivitymean z-score change -0.26 [-0.49, -0.03] down: Decreases global impulsivitymean z-score change -0.28 [-0.52, -0.03] down: Decreases behavioral impulsivitymean z-score change -0.28 [-0.54, -0.02] | Randomized trial1 year | 306 peopleBothmean 65.0 yearsOlder adults; overweight or obesity and metabolic syndrome | Psychotherapy and psychosomatics, Feb 19, 2026 |
down: Decreases frailty−2.5 [−2.9, −2.0] points up: Improves grip strength up: Improves gait speed | Randomized trial24 weeks | 47 peopleage ≥ 70Community‐dwelling frail older adults | Aging cell, Feb 1, 2026 |
up: Improves cognitive functionadjusted mean difference 0.06 (95% CI -0.00 to 0.13), p=0.055 | Randomized trial24 months | 635 peopleOlder adults; in older adults with subjective cognitive decline or mild cognitive impairment | AAIC 2025 abstract, Dec 23, 2025 |
up: Improves cognitive functionfrom 73.94 to 82.32 | Trial | 60-75 yearsOlder adults; mild cognitive impairment | AAIC 2025 abstract, Dec 23, 2025 |
up: Improves cognitive functionβ = 5.93, p = 0.008 | Trial | 284 peopleBothHigh-PRS group | AAIC 2025 abstract, Dec 23, 2025 |
up: Improves lifestyle adherencep = 0.005 up: Improves cognitive functionp = 0.003 | Randomized trial2 years | 1,259 people60-77 yearsOlder adults; at risk of dementia | AAIC 2025 abstract, Dec 23, 2025 |
up: Increases Blautia abundancep = 0.0132 | Trial6 months | 27 peopleOlder adults; Patient cohorts | AAIC 2025 abstract, Dec 23, 2025 |
up: Improves cognitive functiontime*group*ApoE4 interaction p = 0.035 | Review of trials | >=60 yrsOlder adults; ApoE4 carriers vs non-carriers | AAIC 2025 abstract, Dec 23, 2025 |
no change: Has no effect on cognitive function22.8 ± 3.1 to 23.1 ± 3.5 up: Improves food diversity7.5 ± 2.8 to 8.4 ± 2.5, p = 0.008 | Trial12 months | 80 people65–86Older adults | AAIC 2025 abstract, Dec 23, 2025 |
up: Improves cognitive functionES range 0.21 to 0.41 | Randomized trial3 to 6 months | 165 peopleBothmean 70 yearsOlder adults; MCI or SCD and 2 or more dementia risk factors | AAIC 2025 abstract, Dec 23, 2025 |
down: Protects against cognitive frailtyRR: 1.88; 95% CI: 1.24-2.84; p =.003 up: Increases cognitive frailty reversalbetween-group difference −16.6 percentage points; 95% CI: −30.4 to −2.8; p =.018 | Randomized trial2-year | 1,200 people550 (46%) were femalemean age of participants was 69 yearsFinnish adults, aged 60-77 years, recruited from the general population with elevated risk for dementia | The journals of gerontology. Series A, Biological sciences and medical sciences, Dec 16, 2025 |
down: Decreases body weight-6.5%, p<0.005 down: Decreases Framingham risk score-7.6%, p<0.001 down: Decreases atherogenic index of plasma40.0% to 33.6% | Trialone-year | 271 peopleBoth30 to 75 yearsMidlife adults; Older adults; obesity | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |
up: Increases Life's Essential 8+3.3 points (95% CI: 2.1, 4.6) down: Decreases perceived stress scale-1.9 points (95% CI: -2.7, -1.2) | Randomized trial24 weeks | 198 peopleMenmean 54 yearsMidlife adults | AHA Scientific Sessions 2025 abstract, Nov 3, 2025 |
up: Improves cognitive functionZ score difference = 0.107, 95% CI = 0.016 to 0.198 down: Decreases systolic blood pressureAMD = −5.11, 95% CI = −9.16 to −1.07 up: Improves HDL cholesterolAMD = 2.51, 95% CI = 0.53 to 4.49 | Randomized trial18 month | 432 peopleaged 65 to 85 yearsIndividuals aged 65 to 85 years diagnosed with mild cognitive impairment | Alzheimer's & dementia : the journal of the Alzheimer's Association, Nov 1, 2025 |
down: Decreases body weight77.0 [68.0–87.0] kg to 75.9 [67.2–85.7] kg down: Decreases body mass index26.8 [24.4–29.8] to 26.4 [24.1–29.4] down: Decreases waist circumference95 [88.5–103] to 93 [86–101] cm | Trial90 days | 2,300 people18 to 59Broad group of employees aged 18 to 59 in the UAE | International journal of environmental research and public health, Oct 21, 2025 |
up: Improves cognitive functionfrom 21.9 ± 2.9 to 23.3 ± 3.8, p = 0.007 | Trial12 months | 37 peopleBothmean age, 78.6 yearsOlder adults; mild cognitive impairment | Journal of Alzheimer's disease : JAD, Sep 1, 2025 |
up: Improves cognitive function0.045 (0.004 to 0.087) | Randomized trial2-year | 1,177 peopleWomen60-77 yearsOlder adults; higher-risk females (AD-GRS above median) | Brain : a journal of neurology, Aug 1, 2025 |
up: Improves cognitive functionZ-score difference: +0.335, 95% CI: +0.045 to +0.624 no change: Has no effect on cognitive functionZ-score difference: -0.121, 95% CI: -0.353 to +0.110 | Randomized trial18 months | 90 people70-85 yearsOlder adults; in older adults with type 2 diabetes, mild cognitive impairment, and white matter hyperintensities | Diabetes, obesity & metabolism, Jul 14, 2025 |
up: Improves cognitive function+2.5, 95% CI: 1.1-3.9 down: Decreases frailty-1.2, 95% CI: -1.7 to -0.7 down: Decreases depressive symptoms-4.3, 95% CI: -5.6 to -3.0 | Trial6 months | 39 people≥ 60 yearsOlder adults; type 2 diabetes | ADA Scientific Sessions 2025 abstract, Jun 13, 2025 |
up: Improves gait speed0.08 m/s, 95 % CI: 0.03 – 0.13 up: Improves grip strength down: Decreases frailty−0.21, 95 % CI: −0.38 - −0.03 | Randomized trial12 months | 1,082 peoplemean age 75.1 yearsCommunity-dwelling older adults with impaired instrumental activities of daily living, slow gait speed or subjective memory declines | The journal of prevention of Alzheimer's disease, Jun 12, 2025 |
down: Lowers the risk of pre-frailty/frailty-9.6 percentage points (95% CI -16.6-(-2.6)) | Randomized trial2 years (active intervention period), with follow-up to 11 years | 1,201 people551 (46%) were womenmean age 69.3 yearsFinnish older adults aged 60-77 years with elevated risk for dementia based on CAIDE risk score | Journal of the American Geriatrics Society, May 30, 2025 |
up: Improves physical activity up: Improves diet quality no change: Has no effect on self-evaluated health | Randomized trialtwo-year | 1,259 peopleaged 60–77 yearsCommunity-dwelling older participants aged 60–77 years at the beginning of the study and manifesting an elevated risk for developing dementia based on the CAIDE (Cardiovascular Risk Factors, Aging and Dementia) dementia risk score | BMC geriatrics, May 3, 2025 |
down: Decreases subjective cognitive declinep = 0.026 | Randomized trial18 months | 196 peopleolder adultsOlder adults; normal cognition | Journal of Alzheimer's disease : JAD, Apr 22, 2025 |
| Randomized trial2 years | 1,259 people60–77 yearsOlder individuals at risk for dementia | BMC geriatrics, Mar 29, 2025 | |
up: Improves depressive symptoms no change: Has no effect on social inclusion | Randomized trial | Both60-77 yearsOlder adults | Journal of Alzheimer's disease : JAD, Feb 9, 2025 |